Coherus Oncology, Inc. 8K

Coherus and certain subsidiaries entered into a secured term loan facility of up to $100 million with Innovatus Life Sciences Lending Fund I, LP and other lenders, pledging substantially all assets and agreeing to detailed covenants and default terms.

On August 12, 2026, Coherus Oncology, Inc., together with affiliates Coherus Intermediate Corp, Surface Oncology, LLC, and InteKrin Therapeutics Inc. (as co‑Borrowers), entered into a Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP, acting as collateral agent and lender, and other lenders, providing for up to $100 million in term loans (a $55 million Term A Loan, a $25 million Term B Loan subject to milestone and draw-period conditions, and an optional $20 million Term C Loan at the lenders’ discretion). The agreement grants the lenders a first-priority security interest in substantially all of the borrowers’ assets, including equity interests, and contains extensive affirmative and negative covenants, financial reporting obligations, a liquidity covenant, and events of default (including payment, covenant, material adverse effect, insolvency, IP, and listing-related triggers). The loans bear floating interest based on the Prime Rate with a default-rate step‑up, are interest‑only through an initial period with principal amortization thereafter, and are subject to facility, final, prepayment, and potential non‑utilization fees, with mandatory and permitted prepayment provisions and deemed liquidated-damages treatment for the final and prepayment fees upon acceleration or other payoff scenarios.

Filing Facts

CIK

1512762

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-097949

Alert Tier

7